Mir-382–5p targeting il-33 gene as biomarker to predict subclinical atherosclerosis progression in patients with early rheumatoid arthritis
Refereed conference paper presented and published in conference proceedings


Times Cited
Web of Science0WOS source URL (as at 20/09/2021) Click here for the latest count
Altmetrics Information
.

Other information
AbstractBackground: Patients with rheumatoid arthritis(RA) had increased risk of cardiovascular disease(CVD). IL-33, a member of the IL-1 family, plays an important role in the pathogenesis of RA and development of CVD. Yet, plasma IL-33 level was not detectable in most subjects which limits it’s utility as a biomarker for CVD. Meanwhile, microRNAs(miRNAs) targeting IL-33 gene expression might play a role.

Objectives: To ascertain if dysregulated miRNAs targeting IL-33 gene expression in earlyRA patients were associated with subclinical atherosclerosis progression

Methods: 73 ERA patients were recruited for this 1 year cohort study. Potential miRNAs binding to IL-33 gene were predicted by miRanda. 10 miRNAs with the highest possibility of targeting functional sites of IL-33 gene were quantified in cell free plasma samples. cel-miR-39 was used as spike-in control. Carotid plaque(CP) was identified using high-resolution ultrasound annually. Plaque progression(PP) was defined as an increased region harbouring plaque.

Results: CPs were identified in 25 (34%) and 31 (43%) subjects at baseline and month 12 respectively. 16 (22%) subject had plaque progression(PP +group). At baseline, subjects in PP +group were older, with lower pain and patient global scores, a higher proportion on conventional synthetic DMARDs, and higher cardiovascular risk compared to patients without plaque progression (PP-) (table 1). Plasma level of miR-382–5 p in the PP +group was significantly higher than that in the PP- group after adjusting for baseline difference (table 1). Using multivariate logistic regression, miRNA-382–5 p was an independent predictor for plaque progression(OR:2.534, 95%CI=1.079–5.952, p=0.033) after adjustment of baseline characteristics. [AUC:0.66,95% CI:0.51–0.81,p=0.048]. Other independent predictor included higher baseline Framingham risk score, diastolic BP and lower pain score.
All Author(s) ListT.H. Cheng, Q. Shang, E. K. M. Li, M. Li, W.Y. Mak, K.Y. Kwok, I.C.W. Yim, P.C.H. Wong, V.W.N. Lao, S.H.T. Pang, E.W.L. Kun, L.S. Tam
Name of ConferenceAnnual European Congress of Rheumatology (EULAR 2018)
Start Date of Conference13/06/2018
End Date of Conference16/06/2018
Place of ConferenceAmsterdam
Country/Region of ConferenceNetherlands
Proceedings TitleAnnals of the Rheumatic Diseases - Annual European Congress of Rheumatology
Year2018
Month6
Volume Number77
Issue NumberSupplement 2
PublisherBMJ
LanguagesEnglish-United Kingdom

Last updated on 2021-20-09 at 23:06